CRISPR Therapeutics
CRSP

$45.27

0.37%

Market Cap: $3.86B

About: Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.

Employees: 407

Healthcare Biological Products, Except Diagnostic Substances

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 9 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

25% more funds holding in top 10

Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]

23% more repeat investments, than reductions

Existing positions increased: 155 | Existing positions reduced: 126

7% more call options, than puts

Call options by funds: $127M | Put options by funds: $119M

0.79% less ownership

Funds ownership: 70.89% [Q1] → 70.1% (-0.79%) [Q2]

7% less funds holding

Funds holding: 473 [Q1] → 440 (-33) [Q2]

22% less capital invested

Capital invested by funds: $4.14B [Q1] → $3.21B (-$921M) [Q2]

40% less first-time investments, than exits

New positions opened: 50 | Existing positions closed: 83

See Fund Rankings

Research analyst outlook

9 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$59

30%

upside

Avg. target

$82

81%

upside

High target

$105

132%

upside

9 analyst ratings

6 positive

67%

3 neutral

33%

0 negative

0%

Truist Securities Joon Lee 59% 1-year accuracy 20 / 34 met price target	121%upside $100	Buy Maintained	12 Aug 2024
Barclays Gena Wang 27% 1-year accuracy 6 / 22 met price target	30%upside $59	Equal-Weight Maintained	6 Aug 2024
RBC Capital Luca Issi 11% 1-year accuracy 3 / 27 met price target	33%upside $60	Sector Perform Maintained	6 Aug 2024
Stifel Benjamin Burnett 46% 1-year accuracy 6 / 13 met price target	30%upside $59	Hold Maintained	6 Aug 2024
Chardan Capital Geulah Livshits 22% 1-year accuracy 4 / 18 met price target	108%upside $94	Buy Maintained	6 Aug 2024

See Analyst Rankings

Financial journalist opinion

Based on 10 articles about CRSP published over the past 30 days

The Motley Fool

1 Biotech Stock Down 62% to Buy and Hold

CRISPR Therapeutics' lone approved product boasts multibillion-dollar revenue potential. Plus, this promising biotech could succeed in launching other breakthrough therapies.

1 Biotech Stock Down 62% to Buy and Hold

The Motley Fool

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.

3 No-Brainer Biotech Stocks to Buy With $200 Right Now

Zacks Investment Research

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $45.51, representing a +1.42% change from its previous close.

CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why

24/7 Wall Street

2 Biotech Bets to Buy in September

Biotech investing is a thrill-a-minute ride. Biotech stocks can take investors soaring to new heights and fabulous wealth opportunities or send them into the pits of despair.

2 Biotech Bets to Buy in September

The Motley Fool

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?

CRISPR recently obtained approval for Casgevy, a gene-editing therapy which may generate huge revenue. It could take years, however, before the biotech's bottom line starts to show significant improvement.

Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal?

Zacks Investment Research

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics (CRSP) Down 7.7% Since Last Earnings Report?

The Motley Fool

3 Monster Biotech Stocks to Buy Before 2025

Iovance Biotherapeutics is seeing its sales ramp up for the first time. CRISPR Therapeutics has also started to bring in solid revenue.

3 Monster Biotech Stocks to Buy Before 2025

The Motley Fool

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Viking and CRISPR are both doing work in expanding and lucrative areas. They could deliver market-beating returns if they can avoid major headwinds.

Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030

Zacks Investment Research

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Crispr's Casgevy Launch: Promising Start, Uncertain Future

CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy, with revenues significantly below expectations. Financial health of CRISPR is strong, with over 5 years of cash runway, but stock performance has lagged behind S&P 500 returns.

Crispr's Casgevy Launch: Promising Start, Uncertain Future

See News Rankings